JPWO2021067861A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021067861A5 JPWO2021067861A5 JP2022520442A JP2022520442A JPWO2021067861A5 JP WO2021067861 A5 JPWO2021067861 A5 JP WO2021067861A5 JP 2022520442 A JP2022520442 A JP 2022520442A JP 2022520442 A JP2022520442 A JP 2022520442A JP WO2021067861 A5 JPWO2021067861 A5 JP WO2021067861A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- ala
- pharmaceutically acceptable
- acceptable salt
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911060P | 2019-10-04 | 2019-10-04 | |
| US62/911,060 | 2019-10-04 | ||
| PCT/US2020/054137 WO2021067861A1 (en) | 2019-10-04 | 2020-10-02 | Camptothecin peptide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550851A JP2022550851A (ja) | 2022-12-05 |
| JPWO2021067861A5 true JPWO2021067861A5 (he) | 2023-10-04 |
Family
ID=73013821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520442A Pending JP2022550851A (ja) | 2019-10-04 | 2020-10-02 | カンプトテシンペプチドコンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277860A1 (he) |
| EP (1) | EP4037717A1 (he) |
| JP (1) | JP2022550851A (he) |
| KR (1) | KR20220079606A (he) |
| CN (1) | CN114929284A (he) |
| AU (1) | AU2020356955A1 (he) |
| CA (1) | CA3152316A1 (he) |
| IL (1) | IL291686A (he) |
| MX (1) | MX2022003930A (he) |
| WO (1) | WO2021067861A1 (he) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4149559A1 (en) * | 2020-05-13 | 2023-03-22 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| EP4308170A1 (en) | 2021-03-18 | 2024-01-24 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| MX2023010819A (es) * | 2021-03-18 | 2023-09-28 | Seagen Inc | Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos. |
| US20230381321A1 (en) * | 2022-03-17 | 2023-11-30 | Seagan Inc., | Camptothecin conjugates |
| WO2023217227A1 (zh) * | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| WO2023231988A1 (zh) * | 2022-05-30 | 2023-12-07 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法及其中间体 |
| WO2024020734A1 (en) * | 2022-07-25 | 2024-02-01 | Immunogen, Inc. | Novel processes for preparing camptothecin derivatives |
| WO2024049220A1 (ko) * | 2022-08-30 | 2024-03-07 | 주식회사 피노바이오 | 캄토테신계 약물이, 항원 결합 친화도가 낮은 항체에 링커를 통해 연결된 항체-약물 접합체 |
| KR20240035370A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체 |
| CN118105508A (zh) * | 2022-11-29 | 2024-05-31 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| SI0964702T1 (sl) | 1996-08-02 | 2007-02-28 | Ortho Mcneil Pharm Inc | Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer |
| US6629995B1 (en) * | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| ES2396365T3 (es) | 2005-07-29 | 2013-02-21 | Concert Pharmaceuticals Inc. | Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina |
| KR20080047375A (ko) | 2005-07-29 | 2008-05-28 | 콘서트 파마슈티컬즈, 인크. | 약제 화합물 |
| EA020696B1 (ru) * | 2007-10-12 | 2015-01-30 | Сиэтл Дженетикс, Инк. | Способ лечения лимфомы ходжкина с использованием комбинации гемцитабина и конъюгата антитела против cd30 с ауристатином |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| EA037203B1 (ru) | 2012-05-15 | 2021-02-18 | Сиэтл Джинетикс, Инк. | Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами |
| WO2014174111A1 (en) * | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
| EA201690780A1 (ru) | 2013-10-15 | 2016-08-31 | Сиэтл Дженетикс, Инк. | Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство |
| CN111558049B (zh) * | 2013-12-19 | 2024-06-21 | 西雅图基因公司 | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 |
| ES2795818T3 (es) | 2015-03-18 | 2020-11-24 | Seattle Genetics Inc | Anticuerpos CD48 y conjugados de los mismos |
| EP4302784A3 (en) | 2015-06-30 | 2024-03-13 | Seagen Inc. | Anti-ntb-a antibodies and related compositions and methods |
| JP7430643B2 (ja) * | 2018-04-06 | 2024-02-13 | シージェン インコーポレイテッド | カンプトテシンペプチドコンジュゲート |
| IL311437A (he) * | 2018-06-07 | 2024-05-01 | Seagen Inc | תלכידים של קמפטוטצין |
-
2020
- 2020-10-02 WO PCT/US2020/054137 patent/WO2021067861A1/en unknown
- 2020-10-02 CN CN202080080665.1A patent/CN114929284A/zh active Pending
- 2020-10-02 AU AU2020356955A patent/AU2020356955A1/en not_active Abandoned
- 2020-10-02 JP JP2022520442A patent/JP2022550851A/ja active Pending
- 2020-10-02 MX MX2022003930A patent/MX2022003930A/es unknown
- 2020-10-02 EP EP20796991.6A patent/EP4037717A1/en active Pending
- 2020-10-02 CA CA3152316A patent/CA3152316A1/en active Pending
- 2020-10-02 US US17/766,208 patent/US20240277860A1/en active Pending
- 2020-10-02 KR KR1020227015051A patent/KR20220079606A/ko unknown
-
2022
- 2022-03-24 IL IL291686A patent/IL291686A/he unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019195665A5 (he) | ||
| ES2456669T3 (es) | Anticuerpos neutralizantes con especificidad para IL-17 humana | |
| ES2614636T3 (es) | Moléculas de anticuerpos que se unen a IL-17 humana | |
| CA2826564C (en) | Treatment of osteoarthritis and pain | |
| CN111423511A (zh) | 与pd-1结合的抗原结合蛋白 | |
| JP2020509027A5 (he) | ||
| TW201929908A (zh) | 吡咯并苯并二氮呯抗體共軛物 | |
| JPWO2021067861A5 (he) | ||
| AU2013370548A1 (en) | Prolactin receptor binding proteins and uses thereof | |
| TW202108181A (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| CN117279932B (zh) | 依沙替康衍生物及其连接子-负载物和缀合物 | |
| BR112021003843A2 (pt) | biconjugados de folato de anticorpo anti-cd3 e seus usos | |
| JP2020523414A (ja) | Ｌｇｒ５に結合する抗体薬物複合体 | |
| JP2023162163A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| JP2019535716A5 (he) | ||
| ES2926019T3 (es) | Estructuras de anticuerpos para reducir la agregación de anticuerpos multiespecíficos | |
| KR102239752B1 (ko) | 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 | |
| US20210214454A1 (en) | Anti-cd40 antibodies and compositions | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| CN112439060B (zh) | Pd-l1免疫疗法的新用途 | |
| JPWO2019183253A5 (he) | ||
| WO2023051674A1 (zh) | 联合治疗血液肿瘤的抗cd47抗体 |